Timothy Eugene Sullivan is Chief Financial Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 79,174 shares of APLS, which is worth approximately $2.63 Million. The most recent transaction as insider was on Feb 10, 2022, when has been sold 875 shares (Common Stock) at a price of $47.12 per share, resulting in proceeds of $41,230. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 79.2K
0% 3M change
1.88% 12M change
Total Value Held $2.63 Million

Timothy Eugene Sullivan Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 10 2022
SELL
Payment of exercise price or tax liability
$41,230 $47.12 p/Share
875 Reduced 0.84%
103,403 Common Stock
Jan 28 2022
SELL
Payment of exercise price or tax liability
$25,084 $38.59 p/Share
650 Reduced 0.62%
104,278 Common Stock
Jan 21 2022
BUY
Grant, award, or other acquisition
-
30,787 Added 22.69%
104,928 Common Stock
Jun 08 2021
BUY
Exercise of conversion of derivative security
$399,996 $10.03 p/Share
39,880 Added 34.98%
74,141 Common Stock
Feb 10 2021
SELL
Payment of exercise price or tax liability
$40,944 $47.72 p/Share
858 Reduced 2.44%
34,261 Common Stock
Jan 28 2021
BUY
Grant, award, or other acquisition
-
11,250 Added 24.26%
35,119 Common Stock
TES

Timothy Eugene Sullivan

Chief Financial Officer
Waltham, MA

Track Institutional and Insider Activities on APLS

Follow Apellis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS